-- PYC Therapeutics (ASX:PYC) has been cleared by the safety review committee to advance PYC-001 candidate into a multiple ascending dose study in patients with autosomal dominant optic atrophy (ADOA), following positive four-week safety and tolerability results from the 60 microgram single ascending dose trial, according to a Wednesday filing with the Australian bourse.
The company is currently assessing repeat dosing in ADOA patients to evaluate safety and preliminary efficacy, aiming to establish clinical proof of concept before initiating a global registrational trial to support a new drug application, the filing said.
The results from the ongoing phase one and two multiple ascending dose study will be presented throughout 2026 and 2027, the filing added.
The company's shares rose 7% in recent Wednesday trade.